|

Efimosfermin alfa Clinical Trials

6 actively recruiting trials across 6 locations

▲ +3 trials since August 2026

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 4

Top Sponsors

  • GlaxoSmithKline6

Indications

  • Liver Disease6
  • Non Alcoholic Fatty Liver Disease3
  • Metabolic Dysfunction-Associated Steatohepatitis2
  • Liver Diseases, Alcoholic1

Chandler, Arizona1 trial

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

GSK Investigational Site

Phase 3

Little Rock, Arkansas1 trial

A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

GSK Investigational Site

Phase 3

Arcadia, California1 trial

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

GSK Investigational Site

Phase 3

Rialto, California1 trial

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

GSK Investigational Site

Phase 1

Miami, Florida1 trial

A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

GSK Investigational Site

Phase 3

Topeka, Kansas1 trial

A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)

GSK Investigational Site

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.